At the time of writing, Zenas Biopharma Inc [ZBIO] stock is trading at $20.16, up 1.15%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ZBIO shares have gain 25.37% over the last week, with a monthly amount drifted -45.35%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Zenas Biopharma Inc [NASDAQ: ZBIO] stock has seen the most recent analyst activity on January 05, 2026, when Morgan Stanley downgraded its rating to a Equal-Weight but kept the price target unchanged to $19 for it. Previously, Wedbush started tracking the stock with Outperform rating on March 20, 2025, and set its price target to $35. On February 04, 2025, Wolfe Research initiated with an Outperform rating and assigned a price target of $19 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $30 on December 16, 2024. Rodman & Renshaw initiated its recommendation with a Buy and recommended $34 as its price target on November 05, 2024. Morgan Stanley started tracking with an Overweight rating for this stock on October 08, 2024, and assigned it a price target of $40. In a note dated October 08, 2024, Jefferies initiated a Buy rating and provided a target price of $35 on this stock.
For the past year, the stock price of Zenas Biopharma Inc fluctuated between $5.83 and $44.60. Currently, Wall Street analysts expect the stock to reach $37 within the next 12 months. Zenas Biopharma Inc [NASDAQ: ZBIO] shares were valued at $20.16 at the most recent close of the market. An investor can expect a potential return of 83.53% based on the average ZBIO price forecast.
Analyzing the ZBIO fundamentals
Gross Profit Margin for this corporation currently stands at -2.2% with Operating Profit Margin at -13.38%, Pretax Profit Margin comes in at -12.64%, and Net Profit Margin reading is -12.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.59, Equity is -0.74 and Total Capital is -0.74. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Zenas Biopharma Inc [NASDAQ:ZBIO] has a current ratio of 5.66. As well, the Quick Ratio is 5.66, while the Cash Ratio is 2.2. Considering the valuation of this stock, the price to sales ratio is 72.14, the price to book ratio is 4.33.
Transactions by insiders
Recent insider trading involved MOULDER LEON O JR, Chief Executive Officer, that happened on Jan 07 ’26 when 50000.0 shares were purchased. Chief Executive Officer, MOULDER LEON O JR completed a deal on Jan 08 ’26 to buy 30000.0 shares. Meanwhile, Chief Executive Officer MOULDER LEON O JR bought 20000.0 shares on Jan 09 ’26.
